Edema News and Research

RSS

Edema means swelling caused by fluid in your body's tissues. It usually occurs in the feet, ankles and legs, but it can involve your entire body.

High-altitude exposure helps detect early vascular dysfunction

High altitude medicine is a "natural research laboratory" for the study of cardiovascular physiology and pathophysiology. As such, it can shed light on conditions and diseases that mimic the low oxygen content of the atmosphere at the top of mountains. Yves Allemann, MD, FESC, Swiss Cardiovascular Center, University Hospital, Bern, and Urs Scherrer, MD, Centre Hospitalier Universitaire Vaudois, Lausanne, have assembled an international group of leading authorities to contribute to a special issue of Progress in Cardiovascular Diseases.

5 May 2010

Quark to present poster on predicting risk of DGF following machine perfusion of renal transplants at ATC 2010

Quark Pharmaceuticals, Inc., the world leader in clinical development of RNAi-based therapeutics, announced today the presentation of a poster at the 2010 American Transplant Congress titled, "A Nomogram for Predicting Risk of Delayed Graft Function Following Machine Perfusion of Renal Transplants."

5 May 2010

Special issue of Progress in Cardiovascular Diseases

5 May 2010

IBI to present data on Verisome Liquid Drug Delivery System for cystoid macular edema at ARVO 2010

Icon Bioscience, Inc., (IBI), a privately held biopharmaceutical company that specializes in the development and commercialization of novel ophthalmic pharmaceuticals announced today that it will present an abstract demonstrating the utility of its Verisome™ Liquid Drug Delivery System in cystoid macular edema, at the Association for Research in Vision and Ophthalmology (ARVO) 2010 annual meeting, taking place May 2-6, 2010, in Fort Lauderdale, Florida.

5 May 2010

Data from Phase IV study of Bystolic tablets in Hispanic patients with hypertension presented at ASH 2010

Forest Laboratories, Inc. today presented data from a Phase IV study evaluating the effects of Bystolic (nebivolol) tablets in Hispanic patients with hypertension at the 2010 annual scientific meeting of the American Society of Hypertension.

4 May 2010

SARcode presents positive results from Phase 2 study of SAR 1118 ophthalmic solution at Dry Eye Summit

SARcode Corporation, a privately-held biotechnology company focused on developing a novel class of lymphocyte function-associated antigen-1 (LFA-1) antagonists, today announced results of a 230 patient Phase 2 proof-of-concept study evaluating topical SAR 1118 ophthalmic solution in the treatment of aqueous deficient dry eye (keratoconjunctivitis sicca).

3 May 2010

Report shows increasing rates of AMD among Asians

The May issue of Ophthalmology, the journal of the American Academy of Ophthalmology, includes a surprising, first report on increasing rates of age-related macular degeneration among Asians, and describes an innovative "bypass" laser surgery that may help many people with central retinal vein occlusion avoid serious vision loss.

3 May 2010

VIMOVO delayed-release tablets receive FDA approval

AstraZeneca and POZEN Inc. today announced the U.S. Food and Drug Administration has approved VIMOVO (naproxen and esomeprazole magnesium) delayed-release tablets for the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers.

3 May 2010

pSivida announces presentations on bioerodible technologies for degenerative eye disease

pSivida Corp., a leader in the development of back of the eye drug delivery systems, today announced that two poster presentations will be made at the upcoming ARVO meeting on one of pSivida's next generation bioerodible technologies for degenerative eye disease. It marks a key step toward the ability to use pSivida's bioerodible technologies to develop treatments for glaucoma and other degenerative eye diseases, diseases that affect millions of Americans.

30 Apr 2010

REGN reports net loss of $30.5M for first-quarter 2010

Regeneron Pharmaceuticals, Inc. announced financial and operating results for the first quarter of 2010. The Company reported a net loss of $30.5 million, or $0.38 per share (basic and diluted), for the first quarter of 2010 compared with a net loss of $15.4 million, or $0.19 per share (basic and diluted), for the first quarter of 2009.

30 Apr 2010

Nationwide Children's Hospital opens first pediatric Pseudotumor Cerebri Clinic in the U.S.

While most headaches in children can be treated with over-the-counter pain medications or lifestyle changes, it is important to pay attention to their symptoms in case they herald something more serious.

30 Apr 2010

pSivida receives full payment of $15M note from Alimera Sciences

pSivida Corp., a leader in the development of ophthalmic sustained release drug delivery products, today said it had received full payment of a $15 million note, including an additional $225,000 in accrued interest, from Alimera Sciences, Inc., pSivida's licensee developing Iluvien® for the treatment of diabetic macular edema (DME).

29 Apr 2010

Researchers participate in national multi-center trial comparing treatments for diabetic macular edema

A drug may be more effective against the leading cause of adult blindness than laser treatments, a new study has shown.

28 Apr 2010

Ranibizumab eye injections plus laser therapy result in dramatic visual improvement

Researchers have shown that ranibizumab (Lucentis) eye injections, often in combination with laser treatment, result in better vision than laser treatment alone for diabetes-associated swelling of the retina.

28 Apr 2010

DRCR Network study finds new treatment more effective

28 Apr 2010

Better vision ahead for many diabetic retinopathy patients

A nationwide, government-sponsored study finds that people with a common form of diabetic retinopathy can benefit from a medication first developed to combat another potentially blinding disease, age-related macular degeneration (AMD). Treating diabetic macular edema (DME) with ranibizumab (Lucentis) eye injections, plus laser treatment if needed, appears to result in better vision than laser treatment alone, according to the Diabetic Retinopathy Clinical Research (DRCR) Network study published today in Ophthalmology online, the journal of the American Academy of Ophthalmology (Academy). DME is the main cause of vision loss in people with diabetes mellitus.

27 Apr 2010

Salix Pharmaceuticals announces novel patient and health care provider support program for HE

Salix Pharmaceuticals, Ltd. today announced plans for the Hepatic Encephalopathy Living Program (H.E.L.P.). H.E.L.P. is a first-of-its-kind patient and health care provider support program for the management of hepatic encephalopathy (HE) and will launch on May 24, 2010. The program will provide patients with HE educational materials, co-pay assistance, treatment adherence support and a 24-hour toll-free hotline.

27 Apr 2010

Kinetic Concepts introduces V.A.C.Via Therapy System

Kinetic Concepts, Inc. today introduced V.A.C.Via Therapy System, a next-generation negative pressure wound therapy solution that offers clinicians and patients a mobile healing technology with the proven benefits and outcomes of V.A.C. Therapy.

26 Apr 2010

Alimera Sciences prices initial common stock public offering at $11.00 per share

Alimera Sciences, Inc. today announced that it priced its initial public offering of 6,550,000 shares of common stock at a price to the public of $11.00 per share on Wednesday, April 21, 2010.

24 Apr 2010

FDA approves Novartis Pharmaceuticals' Zortress for preventing rejection of kidney transplants

The US Food and Drug Administration (FDA) has approved Zortress® (everolimus) oral tablets for the prevention of rejection of kidney transplants in adult patients at low-to-moderate immunologic risk. Zortress is to be given in combination with reduced doses of the calcineurin inhibitor (CNI) cyclosporine, as well as basiliximab and corticosteroids.

22 Apr 2010

Edema News and Research

Further Reading

High-altitude exposure helps detect early vascular dysfunction

Quark to present poster on predicting risk of DGF following machine perfusion of renal transplants at ATC 2010

Special issue of Progress in Cardiovascular Diseases

IBI to present data on Verisome Liquid Drug Delivery System for cystoid macular edema at ARVO 2010

Data from Phase IV study of Bystolic tablets in Hispanic patients with hypertension presented at ASH 2010

SARcode presents positive results from Phase 2 study of SAR 1118 ophthalmic solution at Dry Eye Summit

Report shows increasing rates of AMD among Asians

VIMOVO delayed-release tablets receive FDA approval

pSivida announces presentations on bioerodible technologies for degenerative eye disease

REGN reports net loss of $30.5M for first-quarter 2010

Nationwide Children's Hospital opens first pediatric Pseudotumor Cerebri Clinic in the U.S.

pSivida receives full payment of $15M note from Alimera Sciences

Researchers participate in national multi-center trial comparing treatments for diabetic macular edema

Ranibizumab eye injections plus laser therapy result in dramatic visual improvement

DRCR Network study finds new treatment more effective

Better vision ahead for many diabetic retinopathy patients

Salix Pharmaceuticals announces novel patient and health care provider support program for HE

Kinetic Concepts introduces V.A.C.Via Therapy System

Alimera Sciences prices initial common stock public offering at $11.00 per share

FDA approves Novartis Pharmaceuticals' Zortress for preventing rejection of kidney transplants

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News